Skip to content

Ozempic side effects: what the label reports

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

The most common Ozempic side effects in the label's placebo-controlled trials were nausea (15.8% at 0.5 mg and 20.3% at 1 mg, against 6.1% on placebo), vomiting (5% and 9.2%), diarrhea (8.5% and 8.8%), abdominal pain (7.3% and 5.7%) and constipation (5% and 3.1%). The trials enrolled adults with type 2 diabetes. Tell your prescriber about persistent or severe abdominal pain or dehydration.

Source: Ozempic FDA label

Key takeaways

  • Nausea, vomiting, diarrhea, abdominal pain and constipation lead the table for adults with type 2 diabetes on Ozempic.
  • Most reports of nausea, vomiting and diarrhea came while the dose was being raised.
  • Ozempic carries a boxed warning, the strongest kind the FDA requires, about thyroid C-cell tumors.
  • It must not be used with a personal or family history of medullary thyroid carcinoma or with MEN 2.
  • Tell your prescriber about persistent or severe abdominal pain, dehydration, low blood sugar or a history of diabetic retinopathy.

How often it was reported in the label's trials

Ozempic: Table 1. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of OZEMPIC-Treated Patients with Type 2 Diabetes Mellitus · Adults with type 2 diabetes in 2 placebo-controlled trials (1 monotherapy trial and 1 trial in combination with basal insulin); mean duration of exposure to Ozempic was 32.9 weeks. The table excludes hypoglycemia.
ReactionPlacebon=262Ozempic 0.5 mgn=260Ozempic 1 mgn=261
Nausea6.1%15.8%20.3%
Vomiting2.3%5%9.2%
Diarrhea1.9%8.5%8.8%
Abdominal pain4.6%7.3%5.7%
Constipation1.5%5%3.1%
Ozempic: Table 2. Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Patients with Type 2 Diabetes Mellitus · Monotherapy stratum of Table 2: adults with type 2 diabetes in a 30-week placebo-controlled monotherapy trial. Severe hypoglycemia means an episode requiring the assistance of another person.
ReactionPlacebon=129Ozempic 0.5 mgn=127Ozempic 1 mgn=130
Severe0%0%0%
Documented symptomatic (≤70 mg/dL glucose threshold)0%1.6%3.8%
Severe or Blood Glucose Confirmed Symptomatic (≤56 mg/dL glucose threshold)1.6%0%0%
Ozempic: Table 2. Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Patients with Type 2 Diabetes Mellitus · Add-on to basal insulin stratum of Table 2: adults with type 2 diabetes in a 30-week placebo-controlled trial of Ozempic added to basal insulin with or without metformin. Severe hypoglycemia means an episode requiring the assistance of another person.
ReactionPlacebon=132Ozempic 0.5 mgn=132Ozempic 1 mgn=131
Severe0%0%1.5%
Documented symptomatic (≤70 mg/dL glucose threshold)15.2%16.7%29.8%
Severe or Blood Glucose Confirmed Symptomatic (≤56 mg/dL glucose threshold)5.3%8.3%10.7%

Ozempic: Gastrointestinal reactions overall

In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving OZEMPIC than placebo (placebo 15.3%, OZEMPIC 0.5 mg 32.7%, OZEMPIC 1 mg 36.4%). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation.

Ozempic: Gastrointestinal reactions with Ozempic 2 mg

In the trial with OZEMPIC 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving OZEMPIC 2 mg (34%) vs OZEMPIC 1 mg (30.8%).

Ozempic: Less common gastrointestinal reactions

In addition to the reactions in Table 1, the following gastrointestinal adverse reactions with a frequency of <5% were associated with OZEMPIC (frequencies listed, respectively, as: placebo; 0.5 mg; 1 mg): dyspepsia (1.9%, 3.5%, 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%).

Ozempic: Hypoglycemia with a sulfonylurea

Severe hypoglycemia occurred in 0.8% and 1.2% of patients when OZEMPIC 0.5 mg and 1 mg, respectively, was coadministered with a sulfonylurea.

Ozempic: Injection site reactions

In placebo-controlled trials, injection site reactions (e.g., injection-site discomfort, erythema) were reported in 0.2% of OZEMPIC-treated patients.

Ozempic: Gallstones (cholelithiasis)

In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients-treated with OZEMPIC 0.5 mg and 1 mg, respectively. Cholelithiasis was not reported in placebo-treated patients.

Ozempic: Heart rate increase

In placebo-controlled trials, OZEMPIC 0.5 mg and 1 mg resulted in a mean increase in heart rate of 2 to 3 beats per minute. There was a mean decrease in heart rate of 0.3 beats per minute in placebo-treated patients.

Ozempic: Acute pancreatitis

In glycemic control trials, acute pancreatitis was confirmed by adjudication in 7 OZEMPIC-treated patients (0.3 cases per 100 patient years) versus 3 in comparator-treated patients (0.2 cases per 100 patient years).

Ozempic: Amylase and lipase increases

In placebo-controlled trials, patients exposed to OZEMPIC had a mean increase from baseline in amylase of 13% and lipase of 22%.

Ozempic: Fatigue, taste changes and dizziness

Other adverse reactions with a frequency of >0.4% were associated with OZEMPIC include fatigue, dysgeusia and dizziness.

Ozempic: Diabetic retinopathy

In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with OZEMPIC (3.0%) compared to placebo (1.8%).

Ozempic: Hair loss (alopecia) and dysesthesia, postmarketing reports without a rate

The following adverse reactions have been reported during post-approval use of semaglutide, the active ingredient of OZEMPIC. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

FDA label: Ozempic, Revised: 5/2026 (DailyMed version 20)

Warnings on the Ozempic label

  • Risk of Thyroid C-Cell Tumors

    Semaglutide caused thyroid C-cell tumors in rodents; whether it does in humans is unknown, and Ozempic is contraindicated with a personal or family history of MTC or with MEN 2.

    It is unknown whether OZEMPIC causes thyroid C-cell tumors, including MTC, in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
  • Acute Pancreatitis

    Acute pancreatitis, including fatal cases, has been seen with GLP-1 receptor agonists including Ozempic; stop the drug if pancreatitis is suspected.

    After initiation of OZEMPIC, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue OZEMPIC and initiate appropriate management.
  • Diabetic Retinopathy Complications

    In a 2-year trial, diabetic retinopathy complications occurred in 3.0% of Ozempic patients versus 1.8% on placebo, with a larger increase in those with existing retinopathy.

    In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with OZEMPIC (3.0%) compared to placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (OZEMPIC 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (OZEMPIC 0.7%, placebo 0.4%).
  • Never Share an OZEMPIC Pen Between Patients

    Ozempic pens must never be shared, even with a new needle, because of infection risk.

    OZEMPIC pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens.
  • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

    Using Ozempic with a sulfonylurea or insulin raises the risk of low blood sugar, which may be reduced by lowering the dose of those medicines.

    The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
  • Acute Kidney Injury Due to Volume Depletion

    Acute kidney injury, sometimes needing dialysis, has been reported, mostly in people dehydrated by nausea, vomiting or diarrhea.

    There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide.
  • Severe Gastrointestinal Adverse Reactions

    Severe gastrointestinal reactions were reported in 0.4% (0.5 mg) and 0.8% (1 mg) of Ozempic patients versus 0% on placebo, and Ozempic is not recommended in severe gastroparesis.

    In OZEMPIC clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving OZEMPIC (0.5 mg 0.4%, 1 mg 0.8%) than placebo (0%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.
  • Hypersensitivity Reactions

    Serious allergic reactions such as anaphylaxis and angioedema have been reported; stop Ozempic if one occurs.

    Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with OZEMPIC. If hypersensitivity reactions occur, discontinue use of OZEMPIC; treat promptly per standard of care, and monitor until signs and symptoms resolve.
  • Acute Gallbladder Disease

    Gallstones were reported in 1.5% (0.5 mg) and 0.4% (1 mg) of Ozempic patients in placebo-controlled trials and in no placebo patients.

    Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients-treated with OZEMPIC 0.5 mg and 1 mg, respectively.
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation

    Because Ozempic slows stomach emptying, rare cases of aspiration during anesthesia or deep sedation have been reported with GLP-1 receptor agonists; tell providers before planned procedures.

    Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking OZEMPIC.

If a side effect has you worried, tell your prescriber about persistent or severe abdominal pain, about nausea, vomiting or diarrhea that leaves you dehydrated, and about signs of low blood sugar if you take insulin or a sulfonylurea. Report signs of a serious allergic reaction too. Dose decisions belong to your prescriber.

The Ozempic injection label reports side effects from trials in adults with type 2 diabetes. Its main table pools two placebo-controlled trials, one of Ozempic alone and one of Ozempic with basal (long-acting) insulin, with a mean exposure of 32.9 weeks. A placebo group gets an inactive treatment instead of the medicine. Ozempic tablets fall under a separate label shared with Rybelsus, covered on the Rybelsus side effects page.

What are the most common side effects of Ozempic?

Five reactions were reported by at least 5% of Ozempic patients. The figures are for 0.5 mg and 1 mg, then placebo.

  • Nausea: 15.8% and 20.3%, with 6.1% on placebo.
  • Vomiting: 5% and 9.2%, with 2.3% on placebo.
  • Diarrhea: 8.5% and 8.8%, with 1.9% on placebo.
  • Abdominal pain: 7.3% and 5.7%, with 4.6% on placebo.
  • Constipation: 5% and 3.1%, with 1.5% on placebo.

The label also says fatigue, taste changes and dizziness were associated with Ozempic at a frequency above 0.4%. Injection site reactions, such as discomfort and redness, were reported by 0.2% of Ozempic patients.

How common are stomach side effects on Ozempic?

Counted together, gastrointestinal (stomach and bowel) reactions were reported by 32.7% of patients on 0.5 mg and 36.4% on 1 mg, against 15.3% on placebo. The label says the majority of reports of nausea, vomiting and diarrhea “occurred during dose escalation,” the weeks when the dose is being raised. In the trial that compared the two higher doses, the figure was 34% on 2 mg and 30.8% on 1 mg.

Below the table’s threshold, the label lists dyspepsia, or indigestion (3.5% on 0.5 mg and 2.7% on 1 mg, against 1.9% on placebo), belching, flatulence (gas), reflux and gastritis.

Severe gastrointestinal reactions were uncommon: 0.4% on 0.5 mg and 0.8% on 1 mg, against 0% on placebo. Ozempic is not recommended in people with severe gastroparesis (a stomach that empties very slowly).

What does the label say about long-term side effects of Ozempic?

One safety finding comes from a 2-year trial in patients with type 2 diabetes and high cardiovascular risk. Diabetic retinopathy complications (eye damage from diabetes) occurred in 3.0% of patients on Ozempic and 1.8% on placebo. The gap was wider among patients who already had retinopathy when the trial began (8.2% against 5.2%) than among those with no known history (0.7% against 0.4%).

The boxed warning is also about duration. It describes thyroid C-cell tumors in rodents as “dose-dependent and treatment-duration-dependent,” and says it’s unknown whether Ozempic causes them in humans.

Does Ozempic cause low blood sugar?

Mostly when it’s combined with other medicines that lower blood sugar. In the trial of Ozempic alone, documented symptomatic hypoglycemia (low blood sugar with symptoms) was reported by 1.6% of patients on 0.5 mg and 3.8% on 1 mg, and no placebo patient. Added to basal insulin, the figures were 16.7% and 29.8%, against 15.2% on placebo, and severe hypoglycemia occurred in 1.5% of patients on 1 mg. With a sulfonylurea, a type of diabetes pill, severe hypoglycemia occurred in 0.8% and 1.2%.

The label says the risk may be lowered by reducing the dose of the sulfonylurea or insulin. That adjustment is your prescriber’s to make.

What is the boxed warning, and what are the serious side effects?

Ozempic carries a boxed warning for thyroid C-cell tumors. A boxed warning is the strongest kind the FDA requires, set apart in a box on the label. Ozempic is contraindicated, meaning it must not be used, in patients with a personal or family history of medullary thyroid carcinoma (MTC) or with MEN 2 (Multiple Endocrine Neoplasia syndrome type 2).

The other warnings in the label:

  • Acute pancreatitis (inflammation of the pancreas): confirmed in 7 Ozempic patients and 3 comparator patients in the glycemic control (blood sugar) trials. Fatal cases have been seen with this class of medicines.
  • Acute gallbladder disease: gallstones were reported in 1.5% of patients on 0.5 mg and 0.4% on 1 mg, and in no placebo patient.
  • Acute kidney injury, sometimes requiring hemodialysis (a machine filters the blood), mostly in people dehydrated by nausea, vomiting or diarrhea.
  • Serious allergic reactions, including anaphylaxis, a sudden and severe whole-body reaction, and angioedema, swelling under the skin.
  • Pulmonary aspiration (stomach contents entering the lungs) during general anesthesia or deep sedation.
  • Pen sharing: Ozempic pens must never be shared, even with a new needle.

The label also records a mean heart rate increase of 2 to 3 beats per minute, and lists alopecia (hair loss) among reactions reported after approval. The safety guide goes through each warning.

How many people stop Ozempic because of side effects?

For stomach and bowel reactions, the label gives 3.1% of patients on 0.5 mg and 3.8% on 1 mg, against 0.4% on placebo.

When to call your prescriber

The label names specific things to report:

  • Persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. The label lists these as signs of acute pancreatitis.
  • Nausea, vomiting or diarrhea that leaves you dehydrated.
  • Signs of low blood sugar, if you take insulin or a sulfonylurea.
  • A history of diabetic retinopathy, given the findings of the 2-year trial.
  • Signs of a serious allergic reaction, and any planned surgery or procedure. The label tells patients to let their healthcare providers know beforehand that they take Ozempic.

Dose decisions belong to your prescriber. The Ozempic guide covers the rest of the label, and the side effects guide compares each reaction across medicines.

Frequently asked questions

What are the most common side effects of Ozempic?

Nausea, vomiting, diarrhea, abdominal pain and constipation. In two placebo-controlled trials in adults with type 2 diabetes, 15.8% of patients on 0.5 mg and 20.3% on 1 mg reported nausea, against 6.1% on placebo. Vomiting was reported by 5% and 9.2%, against 2.3%, and diarrhea by 8.5% and 8.8%, against 1.9%.

How long do Ozempic side effects last?

The label says most reports of nausea, vomiting and diarrhea came during dose escalation, the weeks when the dose is being raised. That describes the whole trial group, not what you personally should expect. If a reaction doesn't ease, raise it with your prescriber.

What are the long-term side effects of Ozempic?

The label reports a 2-year trial in patients with type 2 diabetes and high cardiovascular risk. In it, diabetic retinopathy complications (eye damage from diabetes) occurred in 3.0% of patients on Ozempic and 1.8% on placebo. The boxed warning also describes thyroid C-cell tumors in rodents as dependent on dose and treatment duration, and says it's unknown whether Ozempic causes them in humans.

Does Ozempic cause hair loss?

Hair loss isn't in the Ozempic trial table. The label lists alopecia (hair loss) among reactions reported after approval of semaglutide and gives no rate. It notes that such reports are voluntary and come from a group of uncertain size, so it's not always possible to estimate how often they happen or to establish that the drug caused them.

Is Ozempic safe?

The label doesn't answer with a yes or a no. It carries a boxed warning, the strongest kind the FDA requires: semaglutide causes thyroid C-cell tumors in rodents, and it's unknown whether Ozempic causes them in humans. Ozempic must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Whether it suits you is a decision for your prescriber.

What are the serious side effects of Ozempic?

The label's warnings cover acute pancreatitis, diabetic retinopathy complications, low blood sugar with insulin or a sulfonylurea, acute kidney injury after dehydration, severe stomach and bowel reactions, serious allergic reactions, acute gallbladder disease and pulmonary aspiration during anesthesia. Severe stomach and bowel reactions were reported by 0.4% of patients on 0.5 mg and 0.8% on 1 mg.

Sources (2)

  1. 1.
    FDA label (DailyMed): Ozempic prescribing information, section 4
    “A personal or family history of MTC or in patients with MEN 2”
  2. 2.